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mined after Fisher's Z transformation using GraphPad InStat
program (GraphPad Software, San Diego, CA). Selected correl-
ation pairs are shown in Table II and include all signi®cant
correlation results. The majority of the found correlates were
associated with 6±4 photoproducts of the TT-T type (Table II).
The data would suggest that the skin of subjects with high UCA
levels produce more TT-T lesions and has slower repair of the
those lesions. In contrast, the amount of repaired TT-C
photoproducts after 24 h showed positive correlation to baseline
cis-UCA levels. The immediate post-UV levels of TT=T CPD had
a negative correlation with cis-UCA produced through photo-
isomerization. Because the number of subjects in the analyzes was
only 15±17, however, we have to interpret the data very carefully.
The required sample size would be 30 for detecting the correlation
coef®cient > 0.5 for signi®cance level 0.05 and study power of
80%. A notable general feature might be the tendency of the
parameters to have positive correlation coef®cients except in the
case of TT=T lesions (Table II). The TT=C photoproducts
showed no correlation to UCA. Poor correlation was also seen
between the amount of repaired photoproducts and produced
UCA (Table II, column on the right). There were no signi®cant
differences in the repair kinetics of the photoproduct types,
produced total UCA, or UCA photoisomerization between the
CMM, BCC, and control groups (data not shown).
IJland et al studied photobinding of UCA to DNA (IJland et al,
1998), but possible correlation between the photoreactions of the
two major epidermal chromophores, the production of UCA
isomers and the formation or repair of DNA photoproducts, has
not, to our knowledge, been earlier investigated. The results of our
study suggest that some DNA photoproduct processes induced by
solar-simulating UV irradiation of the human skin may be linked to
epidermal UCA. The marked interindividual variation requires the
results to be con®rmed in a larger study.
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Similar Serum Levels of Soluble Forms of Fas and Fas Ligand
in Cutaneous T Cell Lymphoma and Benign Lymphocyte-
Mediated Dermatoses: Relevancy for Defective Apoptosis
Hypothesis
To the Editor:
Cutaneous T cell lymphomas (CTCL) and especially mycosis
fungoides (MF) and its leukemic counterpart SeÂzary syndrome are
the most frequent primitive lymphomas affecting the skin but their
pathomechanisms remain poorly understood to date (Wood, 1995;
Wood et al, 1997). An attractive hypothesis may consider a chronic
and progressive accumulation of CD4+ lymphocytes in skin rather
than a proliferative disease as a fundamental mechanism in MF, at
least during the early stages. A possible mechanism to explain this
putative accumulation of lymphocytes might be an impairment of
the postactivation apoptosis of a population of CD4+ lymphocytes
bearing membrane molecules that target them to the skin (Picker
et al, 1999). In an earlier series of patients we demonstrated that the
expression of Fas/CD95, one of the major molecules involved in
antigen stimulation-induced apoptosis of T lymphocytes (Lynch et al,
1995; Nagata, 1997; Orteu et al, 1998), was signi®cantly decreased
on CD4+ peripheral lymphocytes in CTCL patients when compared
with benign cutaneous disorders involving lymphocytes, such as
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psoriasis or eczema, a result that might support the theory of
apoptosis impairment in the pathomechanisms of MF (Dereure et al,
2000). The reason underlying this decrease is unclear but two main
hypothesis exist: high levels of soluble Fas ligand in serum of CTCL
patients as already described in other types of lymphomas (Kato et al,
1998), leading to excessive apoptosis of circulating Fas-bearing
lymphocytes and relative increase of Fas negative CD4+ cells;
impairment of Fas expression on a population of CD4+ circulating
lymphocytes, which might correspond to a population of neoplastic
cells originating from the skin, with the possibility of an excessive
production of the soluble form of Fas at the expenses of the
membrane-bound, effective form.
In order to test these different hypothesis and to con®rm earlier
results, we analyzed CD95/Fas expression on CD4+ circulating T
cells in another series of patients with CTCL compared with a
control group of benign lymphocyte-mediated dermatoses, and
simultaneously measured the serum levels of both soluble Fas and
soluble Fas ligand in these two groups. A secondary purpose was to
assess the prognostic signi®cance of serum levels of these two
molecules in CTCL. Nineteen patients with CTCL were selected
for this study, 17 patients with MF ranked according to the Mycosis
Fungoides Cooperative Group (Bunn and Lamberg, 1979): stage Ia
(four patients), Ib (10 patients), and IIb (tumoral, three patients) and
two patients with SeÂzary syndrome. The control group included 18
patients with lymphoid-mediated active benign dermatoses (eight
eczema either atopic or contact dermatitis, seven psoriasis, and
three drug-induced eruptions). Informed consent was obtained
from all patients or healthy donors included in this study. In each
case, blood samples for peripheral lymphocyte phenotyping and
serum was obtained from the same venous puncture. Peripheral
lymphocyte phenotyping for CD3, CD4, and CD95 was carried
out as previously described (Dereure et al, 2000). Soluble Fas and
Fas ligand serum levels were measured by an enzyme-linked
immunosorbent assay kit (Immunotech, Beckman Coulter,
Villepinte, France) according to the manufacturer's instructions.
All the serum samples were analyzed simultaneously for both Fas
and Fas ligand to avoid bias related to analytic conditions variations.
Both ¯ow cytometry and enzyme-linked immunosorbent assay
analysis were carried out before any speci®c treatment was started.
The percentages and absolute numbers of CD4+ and of Fas/CD95+
cells among peripheral blood lymphocytes (PBL) and CD4+ PBL,
respectively, along with serum levels of soluble Fas and Fas ligand
were compared between CTCL and control patients using the
Mann±Wilcoxon±Whitney nonparametric procedure as required
by the size of the samples.
Flow cytometry analysis con®rmed the signi®cant decreased
expression of CD95/Fas on circulating CD4+ cells in CTCL
(mean 6 SEM; 28.5 6 7.2%) when compared with the control
group (mean 6 SEM; 53.8 6 11.3%, p = 0.001). Conversely,
there was no statistical difference between these CTCL and
controls regarding serum rates of soluble Fas [4.04 ng per ml (SEM:
0.43) vs 3.55 ng per ml (SEM: 0.41); p = 0.2] and Fas ligand
[0.056 ng per ml (SEM: 0.01) vs 0.038 ng per ml (SEM: 0.002),
p = 0.12]. No correlation could be found between clinical stage,
lactic dehydrogenase rates and serum levels of Fas or Fas ligand in
the CTCL group. These data are summarized in Table I.
Moreover, no statistical difference was present for soluble Fas or
Fas ligand levels according to the stage of the disease (i.e., stages Ia,
Ib versus IIb and SeÂzary syndrome) or to the level of lactic
dehydrogenase (< 120% of the maximal laboratory value vs
> 120%).
According to these results, decreased Fas/CD95 expression on
peripheral CD4+ lymphocytes in CTCL is unlikely to be linked to
an excess of soluble Fas ligand in serum or to an excessive production
of soluble Fas at the expense of the membrane, apoptosis-inducing,
variant. This decrease seems rather a speci®c feature. The hypothesis
that a subset of CD4+CD95± peripheral cells corresponds to a
population of abnormal, skin-targeted chronically antigen-stimu-
lated, and Fas-induced apoptosis-resistant T cells directly related to
the underlying disease remains valid and prompts further investiga-
tions. This hypothesis is consistent with the detection of circulating
T cell clones in MF by molecular tools, even during the early stages
of the disease (Muche et al, 1997). The search for mutations of fas
gene that have already been reported in other human hematologic
malignancies, such as multiple myeloma (Landowski et al, 1997),
childhood leukemia (Beltinger et al, 1998), adult T-cell leukemia
(Tamiya et al, 1998), and non-Hodgkin lymphoma (Gronbaek et al,
1998), would accordingly be of interest in CTCL.
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Table I. Analysis of CD4 and Fas/CD95 expression on PBL in CTCL benign cutaneous in®ltrates
CTCL patients
mean (6 SEM)
Benign lymphoid in®ltrates
mean (6 SEM) p
Percentage of CD4+ PBL 40.8 (6 9.3)% 37.2 (6 5.7)% NS
Percentage of Fas/CD95+ among CD4+ PBL 28.5 (6 7.2)% 53.8 (6 11.3)% 0.001
Absolute number of CD4+ PBL 663 6 93 .106 per liter 584 6 114.106 per liter NS
Absolute number of Fas/CD95+ among CD4+ PBL 189 6 47.106 per liter 314 6 66.106 per liter 0.001
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